Cardiff Oncology announces special shareholder meeting
CRDF•Votes sought on authorized share increase
Stockholders will be asked to vote to raise Cardiff Oncology's authorized capital stock to 320,000,000 shares from 170,000,000.
The proposal would also increase authorized common stock to 300,000,000 shares from 150,000,000, while authorized preferred stock would remain at 20,000,000 shares.
Stockholders will also vote on a proposal allowing an adjournment to seek additional support if there are not enough votes for the share increase.
Special stockholder meeting scheduled for Oct. 22
Cardiff Oncology will hold a special stockholder meeting in San Diego on Oct. 22, 2026.
